Antiplatelet therapy in non-ST-segment elevation acute coronary syndromes

JAMA

Volumn 292, Issue 15, 2004, Pages 1875-1882

  Schulman, Steven P ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; AMINO ACID RECEPTOR BLOCKING AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCEROL; HEPARIN; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; GLYCERYL TRINITRATE; PEPTIDE; TICLOPIDINE; VASODILATOR AGENT;

ACUTE DISEASE; ADULT; ANAMNESIS; ANGIOPLASTY; ARTICLE; CASE REPORT; HEART MUSCLE ISCHEMIA; HOSPITAL ADMISSION; HUMAN; LABORATORY TEST; MALE; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RISK ASSESSMENT; ST SEGMENT ELEVATION; THROMBOCYTE AGGREGATION; CLINICAL OBSERVATION; CLINICAL STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY THROMBOSIS; DIAGNOSIS; DRUG ANTAGONISM; DRUG COMBINATION; ELECTROCARDIOGRAPHY; MIDDLE AGED; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADRENERGIC BETA-ANTAGONISTS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY BYPASS; CORONARY THROMBOSIS; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; HEPARIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NITROGLYCERIN; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RISK ASSESSMENT; STENTS; TICLOPIDINE; VASODILATOR AGENTS;

EID: 5444230839     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.15.1875     Document Type: Article

References (48)

1. Braunwald E. Application of current guidelines to the management of unstable angina and non-ST-segment elevation myocardial infarction. Circulation. 2003;108(suppl 1):III28-III37.
2. Antman EM, Cohen M, Bernink PJLM, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000;284:835-842.
3. Barrabes J, Figueras J, Moure C, Cortadellas J, Soler-Soler J. Prognostic value of lead aVR in patients with a first non-ST segment elevation acute myocardial infarction. Circulation. 2003;108:814-819.
4. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation. 2004;109(suppl 1):II27-II33.
5. Halcox JP, Schenke WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002;106:653-658.
6. Bogaty P, Hackett D, Davies G, Maseri A. Vasoreactivity of the culprit lesion in unstable angina. Circulation. 1994;90:5-11.
7. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina N Engl J Med. 2002;347:5-12.
8. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient. Circulation. 2003;108:1664-1672.
9. Rioufol G, Finet G, Ginon I, et al. Multiple atherosclerotic plaque ruptures in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation. 2002;106:804-808.
10. Gawaz M, Neumann FJ, Ott I, Schiessler A, Schomig A. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation. 1996;93:229-237.
11. Nair S, Ghosh K, Kulkarni B, Shetty S, Mohanty D. Glanzmann's thrombasthenia: updated. Platelets. 2002;13:387-393.
12. Ambrose JA. Plaque disruption and the acute coronary syndromes of unstable angina and myocardial infarction: if the substrate is similar why is the clinical presentation different? J Am Coll Cardiol. 1992;19:1653-1658.
13. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994;330:1287-1294.
14. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ. 2002;324:71-86.
15. Gum PA, Kottke-Marchant K, Welsh PA, Whilte J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41:961-965.
16. Chen W-H, Lee P-Y, Ng W, Tse H-F, Lau C-P. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol. 2004;43:1122-1126.
17. Alexander JH, Harrington RA, Tuttle RH, et al; PURSUIT Investigators. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. Am J Cardiol. 1999;83:1147-1151.
18. Boersma E, Akkerhus KM, Theroux P, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-segment-elevation acute coronary syndromes: early benefit during medical treatment only, additional protection during percutaneous coronary intervention. Circulation. 1999;100:2045-2048.
19. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomized clinical trials. Lancet. 2002;359:189-198.
20. Peterson ED, Pollack CV, Roe MT, et al. Early use of glycoprotein IIb/IIIa inhibitors in non-ST segment elevation myocardial infarction. J Am Coll Cardiol. 2003;42:45-53.
21. The GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet. 2001;357:1915-1924.
22. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: summary article. Circulation. 2002;106:1893-1900.
23. Steinhubl SR, Talley JK, Braden GA, et al. Point-of-care measured platelet inhibition correlates with the risk of adverse cardiac event following percutaneous coronary intervention: results of the GOLD (Au-assessing Ultegra) multicenter study. Circulation. 2001;103:2572-2578.
24. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. JAMA. 2002;288:2411-2420.
25. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
26. Yusuf S, Mehta SR, Zhao F, et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation. 2003;107:966-972.
27. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003;108:1682-1687.
28. Kastrati A, Mehilli J, Schuhlen H, et al. A clinical trial of abciximab in elective percutaneous intervention after pretreatment with clopidogrel. N Engl J Med. 2004;350:232-238.
29. Dalby M, Montalescot G, Bal dit Sollier C, et al. Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel: results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study. J Am Coll Cardiol. 2004;43:162-168.
30. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908-2913.
31. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109:3171-3175.
32. O'Donnell CJ, Larson MG, Feng DL, et al. Genetic and environmental contributions to platelet aggregation. Circulation. 2001;103:3051-3056.
33. Weiss EJ, Bray PF, Tayback M, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med. 1996;334:1090-1094.
34. Undas A, Sanak M, Musial J, Szczeklik A. Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation. Lancet. 1999;353:982-983.
35. Samani NJ, Lodnick D. Glycoprotein IIIa polymorphism and risk of myocardial infarction. Cardiovasc Res. 1997;33:693-697.
36. Bhatt DL. Aspirin resistance: more than just a laboratory curiosity. J Am Coll Cardiol. 2004;43:1127-1129.
37. Cipollone F, Ciabattoni G, Patrignani P, et al. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina Circulation. 2000;102:1007-1013.
38. Quinn MJ, Aronow HD, Califf RM, et al. Aspirin dose and six-month outcome after an acute coronary syndrome. J Am Coll Cardiol. 2004;43:972-978.
39. Zimmermann N, Wenk A, Kim U, et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation. 2003;108:542-547.
40. 12 gene sequence variations in healthy subjects. Circulation. 2003;108:989-995.
41. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809-1817.
42. Kurth T, Glynn RJ, Walker AM, et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation. 2003;108:1191-1195.
43. Kimmel SE, Berlin JA, Reilly M, et al. The effects of nonselective non-aspirin non-steroidal antiinflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J Am Coll Cardiol. 2004;43:985-990.
44. Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004;109:166-171.
45. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation. Circulation. 2003;107:32-37.
46. Muller I, Besta F, Schulz C, et al. Effects of statins on platelet inhibition by a high loading dose of clopidogrel. Circulation. 2003;108:2195-2197.
47. Saw J, Steinhubl SR, Berger PB, et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled trial. Circulation. 2003;108:921-924.
48. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndrome. N Engl J Med. 2004;350:1495-1504.